IPHARMA was authorized to conduct 2 clinical trials

On November 27, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase I clinical trial of the drug ХС7 (NP THERAPEUTICS).


Protocol № COVID -XC7-01 "A double-blind randomized placebo-controlled Phase I clinical study of the safety, tolerability and pharmacokinetics of ascending doses of XC7 after single and multiple oral administration in healthy volunteers".


The study will be conducted in healthcare facilities of Moscow.


On November 30, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II clinical trial of the drug E6011 (EA Pharma Co., Ltd.).


Protocol № E6011-ET2 "Early Phase II clinical trial of E6011 in patients with active Crohn`s disease".

The study will be conducted in Krasnoyarsk, Novosibirsk, Pyatigorsk, Samara and Saint-Petersburg.


Недавние посты
Архив

© 2021 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon